Background: Biventricular (BiV) stimulation lowers morbidity and mortality in patients with drug-refractory congestive heart failure (CHF), depressed left ventricular (LV) function, and ventricular dyssynchrony in absence of indication for permanent cardiac pacing. This pilot, single-blind, randomized, cross-over study examined the safety and efficacy of upgrading conventional pacing systems to BiV stimulation in patients with advanced CHF.
Methods: We included 56 patients in New York Heart Association (NYHA) functional classes III or IV despite optimal drug treatment and ventricular dyssynchrony (interventriclar delay > 40 ms or LV preejection delay > 140 ms) in need of pacemaker replacement. We compared the patients' functional status, arrhythmias, and standard echocardiographic measurements during 3 months of conventional, single right ventricular (RV) versus 3 months of BiV stimulation.
Results: There were 44 patients in the cross-over phase. QRS duration was shortened by 23% and LV preejection delay by 16% with BiV stimulation. NYHA functional class, 6-minute hall walk and quality of life score were significantly improved with BiV stimulation compared with single RV pacing by 18%, 29%, and 19%, respectively. No significant difference was observed in the ventricular arrhythmia burden or LV reverse remodeling between the 2 periods.
Conclusions: This pilot study showed that upgrading from RV pacing to BiV pacing significantly improves symptoms and exercise tolerance in chronically paced patients with advanced CHF and mechanical dyssynchrony.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1540-8159.2007.00598.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Is Conduction System Pacing Going to Be the New Gold Standard for Cardiac Resynchronization Therapy?
J Clin Med
July 2024
Ordensklinikum Linz Elisabethinen, Fadingerstraße 1, 4020 Linz, Austria.
The current gold standard in device therapy for advanced heart failure (HF), which has been firmly established in HF management for more than 25 years, is classical biventricular pacing (BiV-CRT). In the last decade, a new pacing modality called conduction system pacing (CSP) has emerged as a variant for advanced cardiac device therapy. It provides pacing with preserved intrinsic cardiac activation by direct stimulation of the specific cardiac conduction system.
View Article and Find Full Text PDFUpdate in LV Only Fusion CRT Pacing: Annals and Future Perspectives.
Curr Health Sci J
December 2023
Department of Cardiology, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
Article Synopsis
- Triple-chamber cardiac devices are the standard treatment for heart failure patients, employing biventricular pacing with a right ventricular lead for cardiac resynchronization therapy (CRT).
- Research indicates that the position of the right ventricular lead does not influence the effectiveness of CRT, and excessive right ventricular pacing can negatively impact heart function when the patient has normal conduction.
- The study aims to explore leadless left ventricle fusion pacing as a potential alternative to traditional biventricular pacing, especially for nonischemic heart failure patients with preserved atrioventricular conduction.
Prospective randomized controlled trial of the safety and feasibility of a novel mesenchymal precursor cell therapy in hypoplastic left heart syndrome.
JTCVS Open
December 2023
Department of Cardiac Surgery, Boston Children's Hospital, Boston, Mass.
Objective: To assess the safety and feasibility of low-dose, novel, allogenic mesenchymal precursor cell (MPC) therapy as an adjunct to left ventricular (LV) recruitment for patients with hypoplastic left heart syndrome (HLHS) and borderline left ventricles. MPC injections into the hypoplastic left ventricle may stimulate neovascularization and beneficial LV remodeling and may improve the likelihood of achieving biventricular (BiV) or 1.5 ventricle (1.
View Article and Find Full Text PDFLeft bundle branch area pacing reduces epicardial dispersion of repolarization compared with biventricular cardiac resynchronization therapy.
Heart Rhythm
December 2023
School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom; Department of Cardiology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Background: Biventricular endocardial pacing (BiV-endo) and left bundle branch area pacing (LBBAP) are novel methods of delivering cardiac resynchronization therapy. These techniques are associated with improved activation times and acute hemodynamic response compared with conventional biventricular epicardial pacing (BiV-epi); however, the effects on repolarization and arrhythmic risk are unknown.
Objective: The purpose of this study was to compare the effects of temporary BiV-epi, BiV-endo, and LBBAP on epicardial left ventricular (LV) repolarization using electrocardiographic imaging (ECGi).
Biventricular versus left ventricular only stimulation: an echocardiographic substudy of the B-LEFT HF trial.
J Cardiovasc Med (Hagerstown)
July 2023
CHU Pontchaillou, Rennes, France.
Background: The noninferiority of left ventricular pacing alone (LVp) compared with biventricular pacing (BIV) has not been yet definitely documented. In this study, we reviewed all the original echocardiographic measures of the Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial in order to investigate mechanisms underlying LV remodelling with both pacing modalities.
Methods: Patients with New York Heart Association functional class (NYHA) III or IV despite optimal medical therapy, LVEF 35% or less, left ventricular end-diastolic diameter (LVEDD) more than 55 mm, QRS duration at least 130 ms were randomized to BIV or LVp for 6 months.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!